Patients will receive Neoadjuvant therapy with IPH5201 and durvalumab in addition to standard chemotherapy.
Following surgery, patients will receive adjuvant treatment with IPH5201 and durvalumab.
Patients will receive Neoadjuvant therapy with IPH5201 and durvalumab in addition to standard chemotherapy.
Following surgery, patients will receive adjuvant treatment with IPH5201 and durvalumab.
- Durvalumab
- MEDI4736, IMFINZI
- Carboplatin/Paclitaxel Carboplatin/Paclitaxel, as chemotherapy
- Pemetrexed/Cisplatin Pemetrexed/Cisplatin as chemotherapy
- Pemetrexed/Carboplatin Pemetrexed/Carboplatin as chemotherapy
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
